Meeting
2012 ASCO Annual Meeting
ABT-888 (veliparib) in combination with weekly carboplatin and paclitaxel in advanced solid tumors.
Authors
Jorge Arturo Rios-Perez
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Jorge Arturo Rios-Perez , Jan H. Beumer , Leonard Joseph Appleman , Hussein Abdul-Hassan Tawbi , Edward Chu , Ronald G. Stoller , Chandra Prakash Belani , Yixing Jiang , Robert W. Sobol Jr., Stacie Peacock Shepherd , Vincent L. Giranda , Alice P. Chen , Shannon Leigh Huggins-Puhalla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01281150
Citation
J Clin Oncol 30, 2012 (suppl; abstr TPS1138)
DOI
10.1200/jco.2012.30.15_suppl.tps1138
Abstract #
TPS1138
Poster Bd #
35G
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.
First Author: Katherine M. Bell-McGuinn
Poster
2021 ASCO Annual Meeting
Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.
First Author: Ecaterina Elena Dumbrava
Poster
2018 ASCO Annual Meeting
NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
First Author: Anita Ahmed Turk
Poster
2016 ASCO Annual Meeting
A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.
First Author: Fangfei Gao